3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Conditions
Carcinoma, Hepatocellular
19
Carcinoma, Renal Cell
13
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Endometrial Neoplasms
6
Neoplasms
4
Biliary Tract Neoplasms
4
Neuroendocrine Tumors
3
Melanoma
3
Liver Neoplasms
3
Vulvar Neoplasms
2
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
von Hippel-Lindau Disease
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Penile Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Lung Neoplasms
1
Kidney Neoplasms
1
Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
1
Interventions
pembrolizumab
3
lenvatinib
2
Specimen Handling
2
Nivolumab
2
Cisplatin
2
trastuzumab deruxtecan
1
tivozanib
1
liposomal doxorubicin
1
entinostat
1
dostarlimab
1
bintrafusp alfa protein, human
1
atezolizumab
1
Therapeutic Touch
1
Surveys and Questionnaires
1
Radiotherapy
1
Radiation
1
Platinum
1
Paclitaxel
1
Nelfinavir
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Gemcitabine
1
Doxorubicin
1
Dehydroepiandrosterone
1
CTLA-4 Antigen
1
Bupropion
1
Blood Specimen Collection
1
Bevacizumab
1
Axitinib
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Vulvar Neoplasms
×
lenvatinib
×
90 days
×
Clear all
NCT05903833
2026-05-11
PIERCE
AGO Research GmbH
Phase 2
Recruiting
42 enrolled
NCT07290894
2026-04-02
MITO VULVA-01
National Cancer Institute, Naples
Phase 2
Recruiting
80 enrolled